Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGFR | P43088 | 15/20 | 0.78 |
| ▸ | PTGER3 | P43115 | 8/20 | 0.78 |
| ▸ | TBXA2R | P21731 | 5/20 | 0.78 |
| ▸ | PTGER1 | P34995 | 4/20 | 0.78 |
| ▸ | THRB | P10828 | 1/20 | 0.70 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.70 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.57 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.57 |
| ▸ | SLCO2A1 | Q92959 | 1/20 | 0.57 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tiaprost SCHEMBL12495592 | 1.00 | PTGFR (0.78) | PTGFRPTGER3TBXA2RPTGER1THRB | |
| Tiaprost SCHEMBL14511288 | 1.00 | PTGFR (0.78) | PTGFRPTGER3TBXA2RPTGER1THRB | |
| Tiaprost SCHEMBL867741 | 1.00 | PTGFR (0.78) | PTGFRPTGER3TBXA2RPTGER1THRB | |
| Tiaprost SCHEMBL12495595 | 1.00 | PTGFR (0.78) | PTGFRPTGER3TBXA2RPTGER1THRB | |
| SCHEMBL10024575 | 0.88 | PTGFR (0.63) | PTGFRPTGER3TBXA2RPTGER1THRB | |
| SCHEMBL10057560 | 0.88 | PTGFR (0.63) | PTGFRPTGER3TBXA2RPTGER1THRB | |
| SCHEMBL20573392 | 0.88 | PTGFR (1.00) | PTGFRPTGER3TBXA2RPTGER1THRB | |
| SCHEMBL13399717 | 0.88 | PTGFR (1.00) | PTGFRPTGER3TBXA2RPTGER1THRB | |
| SCHEMBL3368370 | 0.88 | PTGFR (1.00) | PTGFRPTGER3TBXA2RPTGER1THRB | |
| SCHEMBL3368364 | 0.88 | PTGFR (1.00) | PTGFRPTGER3TBXA2RPTGER1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8557860-B2 | Cyclopentane heptan(ENE)OIC acid, 2-heteroarylalkenyl derivatives as therapeutic agents | ALLERGAN, INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-8557860-B2 | Cyclopentane heptan(ENE)OIC acid, 2-heteroarylalkenyl derivatives as therapeutic agents | ALLERGAN, INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-20110082184-A1 | CYCLOPENTANE HEPTAN(ENE)OIC ACID, 2-HETEROARYLALKENYL DERIVATIVES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| US-7906552-B2 | Compounds for prodrug for bonding, using prostaglandins | ALLERGAN, INC. (US) | 2011-03-15 | — | — | US | disclosed |
| US-7906552-B2 | Compounds for prodrug for bonding, using prostaglandins | ALLERGAN, INC. (US) | 2011-03-15 | — | — | US | disclosed |
| US-7863319-B2 | Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents | ALLERGAN, INC. (US) | 2011-01-04 | — | — | US | disclosed |
| US-7863319-B2 | Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents | ALLERGAN, INC. (US) | 2011-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082184-A1 | CYCLOPENTANE HEPTAN(ENE)OIC ACID, 2-HETEROARYLALKENYL DERIVATIVES AS THERAPEUTIC AGENTS | PTGIR, GLI1, SQLE | PTGFR 115/4885PTGER3 27/4885TBXA2R 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.